A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis

ImproveCareNow respects your privacy. We will not share your information inappropriately. Your address, while not required, provides information about your geographic area and helps ImproveCareNow know which care centers are near you. In the future ImproveCareNow may contact you with information specific to your area or care center. ImproveCareNow email lists are managed through Nationbuilder. If you have questions please contact us. You may unsubscribe at any time if you do not wish to hear from ImproveCareNow in the future. Read our full Privacy Policy.